Get the Stockscreener App
33.10
1.11%
-0.37
Septerna Inc stock is traded at $33.10, with a volume of 242.03K.
It is down -1.11% in the last 24 hours and down -8.18% over the past month.
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.
See More
Previous Close:
$33.47
Open:
$33.88
24h Volume:
242.03K
Relative Volume:
0.60
Market Cap:
$1.49B
Revenue:
$45.95M
Net Income/Loss:
$-48.88M
P/E Ratio:
-29.74
EPS:
-1.1129
Net Cash Flow:
$109.67M
1W Performance:
-0.90%
1M Performance:
-8.18%
6M Performance:
+28.47%
1Y Performance:
+144.10%
1-Day Range:
$32.48
$34.97
1-Week Range:
$31.85
$35.11
52-Week Range:
$10.62
$38.04
Septerna Inc Stock (SEPN) Company Profile
Name
Septerna Inc
Sector
Industry
Phone
650-338-3533
Address
250 EAST GRAND AVENUE, SUITE 65, SOUTH SAN FRANCISCO
Compare SEPN vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SEPN
Septerna Inc
|
33.10 | 1.49B | 45.95M | -48.88M | 109.67M | -1.1129 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Septerna Inc Stock (SEPN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-25 | Initiated | Raymond James | Strong Buy |
| Dec-15-25 | Initiated | Truist | Buy |
| Nov-14-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jun-23-25 | Initiated | H.C. Wainwright | Buy |
| Feb-18-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-19-24 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-19-24 | Initiated | JP Morgan | Overweight |
| Nov-19-24 | Initiated | TD Cowen | Buy |
| Nov-19-24 | Initiated | Wells Fargo | Overweight |
View All
Septerna Inc Stock (SEPN) Latest News
3 Small-Cap Stocks with ‘Strong Buy’ Ratings and 40%+ Upside, According to Analysts - TipRanks
Septerna President and COO Elizabeth Bhatt sells 4,000 shares for $135,974 - Bitget
Septerna president & COO Elizabeth Bhatt sells $135,974 in stock - Investing.com
Form 4 Septerna Inc For: 17 July By Investing.com - Investing.com Nigeria
Septerna (SEPN) president sells 4,000 shares and exercises 4,000 options under plan - Stock Titan
Septerna (SEPN) 10K Form and Latest SEC Filings 2026 - MarketBeat
Septerna, Inc. (SEPN) Reports Q3 Loss, Misses Revenue Estimates - MSN
Septerna, Inc. SEC Filing (Jul 15, 2026) - Stock Titan
Septerna Inc. (SEPN) Declines 1.33%, Approaching Key Support at $32.38Relative Volume - dars.gov.et
Is Septerna (SEPN) Fully Valued Following Its Russell Index Inclusions? - simplywall.st
Septerna (SEPN) Is Up 7.1% After Broad Russell Growth Index Additions Has The Bull Case Changed? - Sahm
Septerna Inc stock hits all-time high at 38.01 USD - Investing.com UK
Septerna Inc stock hits all-time high at 38.01 USD By Investing.com - Investing.com Australia
Septerna (SEPN) 43rd Annual J.P. Morgan Healthcare Conference 2025 Summary - Quartr
SEPN Q1 2026 Earnings: Smaller-than-expected loss as clinical-stage biotech advancesEarnings Yield Spread - dars.gov.et
Septerna's Chief People Officer Sold Nearly 12,000 Company Shares. What Does That Mean for Investors? - Yahoo Finance
Septerna's Chief People Officer Sold Nearly 12,000 Company Shares. What Does That Mean for Investors? - The Motley Fool
Septerna Inc. (SEPN) Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Steady Pipeline ProgressRevenue Surprise History - dars.gov.et
Septerna (SEPN) SVP Long exercises options and sells 3,333 shares in Rule 10b5-1 trades - Stock Titan
Is Septerna, Inc. (SEPN) Stock a Biotech Opportunity With a Potential First-in-Class Hypoparathyroidism Treatment? - Yahoo Finance
Septerna Inc. (SEPN) Slides 2.63% as Stock Tests Key Support Near $32Max Pain Level - dars.gov.et
Analysts Offer Insights on Technology Companies: Septerna, Inc. (SEPN) and Strategy (MSTR) - The Globe and Mail
Septerna Inc. (SEPN) Slips 1.79% as Stock Tests Key Support LevelsInitial Balance - dars.gov.et
Guggenheim cuts Septerna stock price target to $45 on CSU study risk By Investing.com - Investing.com India
SEPN Maintained by Guggenheim -- Price Target Lowered to $45.00 - GuruFocus
Truist Securities Adjusts Septerna Price Target to $43 From $35, Maintains Buy Rating - marketscreener.com
SEPN Maintains Buy RatingPrice Target Raised to $43.00 by Tru - GuruFocus
SEPN Reiterated by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus
Septerna (SEPN) Is Down 7.1% After Broad Russell Index Additions Has The Bull Case Changed? - simplywall.st
Guggenheim cuts Septerna stock price target to $45 on CSU study risk - Investing.com South Africa
Analysts Are Bullish on Top Technology Stocks: Akamai (AKAM), Procore Technologies (PCOR) - The Globe and Mail
Septerna stock maintained at Buy by H.C. Wainwright after rival setback - Investing.com
H.C. Wainwright Maintains Septerna(SEPN.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Truist raises Septerna stock price target to $43 on hypoparathyroidism outlook - Investing.com
5 Best Up and Coming Pharmaceutical Stocks to Buy Now - Insider Monkey
Septerna, Inc. Files 8-K Detailing Annual Meeting Results and Company Information – June 2026 - Minichart
Septerna chief people officer Samira Shaikhly sells $76,622 in stock - Investing.com UK
Form 4 Septerna Inc For: 30 June By Investing.com - Investing.com UK
Septerna (NASDAQ: SEPN) director-linked funds get 15,000-share option - Stock Titan
Septerna chief people officer Samira Shaikhly sells $76,622 in stock By Investing.com - Investing.com South Africa
Septerna (SEPN) CPO exercises options and sells 2,178 shares - Stock Titan
Septerna (SEPN) director Bernard Coulie receives 15,000 stock options - Stock Titan
Septerna (SEPN) director Abraham Bassan receives grant of 15,000 stock options - Stock Titan
Septerna (SEPN) director granted 15,000 options for RA Capital funds - Stock Titan
Septerna (NASDAQ: SEPN) 2026 meeting elects directors and backs EY as auditor - Stock Titan
SEPN Q1 2026 Earnings: EPS Beat of 55.3% Overshadowed by Pre-Revenue StatusSurprise Factor Analysis - dars.gov.et
Cantor Fitzgerald Maintains Septerna(SEPN.US) With Buy Rating, Raises Target Price to $60 - Moomoo
Septerna Inc. (SEPN) Q1 2026 Earnings: Smaller-Than-Expected Loss as Biotech Advances PipelineEarnings Manipulation Risk - dars.gov.et
Is Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares? - Yahoo Finance
Septerna Inc Stock (SEPN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):